Cite
Galluppi GR, Brar S, Caro L, et al. Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. Clin Pharmacol Ther. 2021;110(5):1172-1175doi: 10.1002/cpt.2265.
Galluppi, G. R., Brar, S., Caro, L., Chen, Y., Frey, N., Grimm, H. P., Rudd, D. J., Li, C. C., Magee, M., Mukherjee, A., Nagao, L., Purohit, V. S., Roy, A., Salem, A. H., Sinha, V., Suleiman, A. A., Taskar, K. S., Upreti, V. V., Weber, B., & Cook, J. (2021). Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. Clinical pharmacology and therapeutics, 110(5), 1172-1175. https://doi.org/10.1002/cpt.2265
Galluppi, Gerald R, et al. "Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program." Clinical pharmacology and therapeutics vol. 110,5 (2021): 1172-1175. doi: https://doi.org/10.1002/cpt.2265
Galluppi GR, Brar S, Caro L, Chen Y, Frey N, Grimm HP, Rudd DJ, Li CC, Magee M, Mukherjee A, Nagao L, Purohit VS, Roy A, Salem AH, Sinha V, Suleiman AA, Taskar KS, Upreti VV, Weber B, Cook J. Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. Clin Pharmacol Ther. 2021 Nov;110(5):1172-1175. doi: 10.1002/cpt.2265. Epub 2021 May 15. PMID: 33991429; PMCID: PMC8596613.
Copy
Download .nbib